IAS 2017: Closing ceremony exposes Gilead Sciences
Conference funders, Gilead Sciences, named and shamed for its “insatiable greed” Yesterday, the 9th International AIDS Conference on HIV Science...
BLOG: We want dolutegravir for all, and we want it now
Author: Othoman Mellouk, Intellectual Property and Access to Medicines Lead at the International Treatment Preparedness Coalition (ITPC). Article first published...
Victory: Gilead forced to withdraw Truvada® patent application in Argentina
Gilead prevented from obtaining an illegitimate monopoly at the expense of people’s health Activists in Argentina, including our partner...
Ukraine: HIV patients appeal against deadly patent monopoly
Unmerited patents protecting profit not patients – protesting & appealing the decisions so far. 50% of Ukraine’s budget for HIV...
#TreatPeopleRight – Highlights from the ITPC Annual Review
Campaign activity contributing to combined savings of US$700 million for health budgets is among ITPC’s 2016 highlights The mission of...
Thai decision to ‘speed up’ drug patents would threaten access to medicines
Global community on access to medicines calls on Thai PM to retain a pro public health stance. The Thai...
Argentina: GEP filed new opposition to patent request for Hepatitis C drug
A significant step in ensuring access to treatment for the 800,000 people living with hepatitis C in Argentina. Earlier this...
All-Ukrainian Network of PLHIV continues to struggle for affordable LPV/r
Network of people living with HIV submits second opposition to patent on essential HIV drug in Ukraine On 30 January...
Brazilian National Institute of Industrial Property Rejects Truvada® Patent Application
On 24 January 2017, Brazil’s National Institute of Industrial Property (INPI) made public a decision to reject the patent application...
Open Letter to WHO Director General, Margaret Chan
Civil Society Open Letter urging WHO to include UN High Level Panel on Access to Medicines Report on WHO Board Agenda